CDKN2A and cancer: The development of effective therapies achieved for other common cancers (e.g. breast, prostate, colorectal) has so far eluded PDA, despite the vastly improved understanding of underlying genetic alterations (e.g. KRAS, p16/CDKN2A, TP53) and dysregulated signaling pathways involved in pancreatic tumorigenesis [2–5].